Pediatric Primary Immunodeficiency Disease (PID) in China

Clinical Characteristics and Prognosis of Primary Immunodeficiency Disease (PID) in Chinese Children

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03252548

Enrollment

400

Registered

2017-08-17

Start date

2018-01-31

Completion date

2022-08-31

Last updated

2018-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Immunodeficiency Disease

Brief summary

This study is a prospective cohort study of children diagnosed with primary immunodeficiency disease (PID). The aim is to investigate the clinical characteristics and prognosis of PID in Chinese children.

Detailed description

Primary immunodeficiency disease (PID) is a group of rare and fatal disease. However, the research about clinical characteristics, treatment, management and prognosis of Chinese children with PID is still not perfect and there is no basic and large database. Therefore, this study is conducted, in order to set up a complete database and long term follow up of Chinese children with PID, and establish foundations for basic research and precise medicine. This study is divided into two parts. In part one, pediatric patients with PID in the past 10 years will be collected retrospectively by review medical records from these centers, and investigate the clinical features and prognosis. In part two, all new cases with suspected PID will be collected. Clinical symptoms, physical examination, blood tests, and humoral and cellular immune functions will be detected. Gene tests would be done when necessary to confirm the diagnosis. Then follow up at 6-moth, 1-year, 2-year, 3-year, 4-year and 5-year respectively. The trial will be completed in 60 months.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Days to 18 Years

Healthy volunteers

Inclusion criteria

1. Age: from neonates to 18 years old 2. Fulfilling the one of the followings: 1. Severe infection after vaccination (BCG, polio arthritis pill) 2. Chronic/recurrent ear infection, sinus infections and respiratory tract infection 3. Recurrent, deep skin or deep-seated infections 4. Boys with early period and refractory thrombocytopenia 5. Infants with obviously decreased absolute number of lymphocytes 6. Severe allergy with infection 7. Infant diabetes with severe diarrhea 8. Boys with severe Epstein-Barr virus infection 9. Infants with hepatosplenomegaly and generalized lymphadenopathy 10. Infantile hemophagocytic syndrome 11. Failure of an infant to gain weight or grow normally 12. Persistent thrush in mouth or fungalinfection on skin 13. Family history of primary immunodeficiency 14. Invasive pneumococcal infection 15. Erythrodermic psoriasis 3. Gene test confirmed PID pediatric patients

Exclusion criteria

Subject will be excluded if she or he would not enroll into this study

Design outcomes

Primary

Measure	Time frame	Description
Frequencies of severe infection of children with PID	60 months	Times of severe infection attack will be recorded every year from baseline to 60 months, assessed by questionnaire

Secondary

Measure	Time frame	Description
Life quality of children with PID	60 months	Life Quality Questionnaire, once for every year
Complications of children with PID	60 months	—
Long-term changes on lung function of children with PID	60 months	—

Contacts

Primary Contactbaoping xu, MD,PhD

xubaopingbch@163.com861059616308

Outcome results